by Ben Paylor | Oct 24, 2014
> Just over one year ago, we launched the pilot phase of an animation project titled StemCellShorts here on Signals blog. Funded by a Stem Cell Network Public Outreach Award, the project was very much an experiment for us to see what would happen when you tasked a...
by Mark Curtis | Oct 14, 2014
. Welcome to your Update from the Clinic for the month of September. There’s a mixture of news from the cancer stem cell companies and immunotherapy companies this past month. Amongst other things, the FDA removed the previously imposed partial hold on one of...
by Mark Curtis | Sep 18, 2014
. Welcome to your Update from the Clinic for the month of August. Asterias Biotherapeutics breathes new life into a cell therapy shelved two years ago and initiates a Phase I/II study in patients with spinal cord injury. Northwest Biotherapeutics provides an update on...
by David Brindley | Sep 16, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. Consider this question: if I gave you the option to take a drug offering a 100 percent chance...
by Lisa Willemse | Jul 14, 2014
Written with contributions from Geoff Lomax, CIRM’s Senior Officer for Medical and Ethical Standards and Rosario Isasi, Research Associate at McGill University and Academic Secretary for the International Stem Cell Forum Ethics Working Party. Portions of this post...
by David Kent | Jun 26, 2014
> The cellular therapy plenary at the ISSCR conference on June 19 was an incredibly interesting mix of hope and despair. On one hand, the opening talk by Leigh Turner made us imagine thousands of people in the United States getting duped into stem cell therapies as...
Comments